TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma

BACKGROUND: Immunotherapy has facilitated great breakthroughs in the treatment of hepatocellular carcinoma (HCC). However, the efficacy and response rate of immunotherapy are limited and vary among different patients with HCC. TP53 mutation substantially affects the expression of immune checkpoint m...

Descripción completa

Detalles Bibliográficos
Autores principales: Yu, Jiongjie, Ling, Sunbin, Hong, Jiachen, Zhang, Lincheng, Zhou, Wei, Yin, Lu, Xu, Shengjun, Que, Qingyang, Wu, Yongfeng, Zhan, Qifan, Bao, Jiaqi, Xu, Nan, Liu, Yuchen, Chen, Kangchen, Wei, Xuyong, Liu, Zhikun, Feng, Tingting, Zhou, Lin, Xie, Haiyang, Wang, Shuai, Liu, Jimin, Zheng, Shusen, Xu, Xiao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Basic Tumor Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689408/
https://www.ncbi.nlm.nih.gov/pubmed/38030304
http://dx.doi.org/10.1136/jitc-2023-007479

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10689408/
https://www.ncbi.nlm.nih.gov/pubmed/38030304
http://dx.doi.org/10.1136/jitc-2023-007479

Ejemplares similares